Diagnostic and prognostic value of preoperative combined GFAP, IGFBP‐2, and YKL‐40 plasma levels in patients with glioblastoma

• Published in: Cancer 2014-12, Vol.120 (24), p.3972-3980
• Main Authors: Gállego Pérez‐Larraya, Jaime, Paris, Sophie, Idbaih, Ahmed, Dehais, Caroline, Laigle‐Donadey, Florence, Navarro, Soledad, Capelle, Laurent, Mokhtari, Karima, Marie, Yannick, Sanson, Marc, Hoang‐Xuan, Khê, Delattre, Jean‐Yves, Mallet, Alain
• Format: Article
• Language: English
• Subjects: Adipokines - blood; Adult; Aged; Aged, 80 and over; Biological and medical sciences; biomarkers; Biomarkers, Tumor - blood; Brain Neoplasms - blood; Brain Neoplasms - diagnosis; Brain Neoplasms - surgery; Chitinase-3-Like Protein 1; chitinase‐3; Female; glial fibrillary acidic protein (GFAP); Glial Fibrillary Acidic Protein - blood; Glioblastoma - blood; Glioblastoma - diagnosis; Glioblastoma - surgery; glioblastoma multiforme; Humans; Insulin-Like Growth Factor Binding Protein 2 - blood; insulin‐like growth factor‐binding protein 2 (IGFBP‐2); Lectins - blood; like protein 1 (YKL‐40); Male; Medical sciences; Middle Aged; Multiple tumors. Solid tumors. Tumors in childhood (general aspects); Neurology; plasma; Predictive Value of Tests; Preoperative Period; Prognosis; Tumors; Tumors of the nervous system. Phacomatoses; Young Adult
• ISSN: 0008-543X; 1097-0142
• DOI: 10.1002/cncr.28949

BACKGROUND Circulating proteins released by tumor cells have recently been investigated as potential single surrogate biomarkers for glioblastoma multiforme (GBM). The aim of the current hypothesis‐generating study was to evaluate the diagnostic and prognostic role of preoperative insulin‐like growth factor‐binding protein 2 (IGFBP‐2), chitinase‐3‐like protein 1 (YKL‐40), and glial fibrillary acidic protein (GFAP) plasma levels in patients with GBM, both as single markers and as a combined profile. METHODS Plasma samples from 111 patients with GBM and a subset of 40 patients with nonglial brain tumors were obtained preoperatively. Plasma from 99 healthy controls was also analyzed. IGFBP‐2, YKL‐40, and GFAP levels were determined using enzyme‐linked immunoadsorbent assay tests. Their association with histological and radiological variables was assessed. RESULTS Circulating levels of all 3 proteins were found to be significantly higher in patients with GBM compared with healthy controls (P < .01). Only YKL‐40 and GFAP were found to demonstrate significant differences between patients with GBM and nonglial brain tumors (P = .04). GFAP was undetectable (